




The relative strengths and weaknesses of PUMA Biotechnology INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA Biotechnology INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 104% points. The greatest weakness of PUMA Biotechnology INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 259%, being 45% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	147,658
Cost of Goods Sold	64,404
Intangible Assets	0
Liabilities, Current	96,111
Liabilities, Non-Current	23,334
Other Assets	65,160
Other Compr. Net Income	10
Other Expenses	-6,178
Other Liabilities	1,763
Other Net Income	-6,866
Other Revenues	230,468
Property and Equipment	515
Research and Development	54,935
Selling, General and Administrative Expense	80,163

Output Variable	Value in 1000 USD
Assets	213,333
Liabilities	121,208
Expenses	193,324
Revenues	230,468
Stockholders Equity	92,125
Net Income	30,278
Comprehensive Net Income	30,283
BaseVar	382,604
ECR before LimitedLiability	138%
Economic Capital Ratio	259%